Lexaria Bioscience
Kelowna
About Lexaria Bioscience
Lexaria Bioscience Corp. has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules. Lexaria’s DehydraTECHTM delivery technology is protected by a robust suite of patents granted or pending worldwide and is proven effective in multiple international studies in greatly assisting rapidity and quantity of absorption of a range of lipophilic (i.e., fat-soluble), bioactive molecules. By significantly enhancing the performance and experience with oral ingestion, Lexaria’s DehydraTECH delivery technology offers a viable and often healthier alternative to other delivery methods for bioactive substances in widespread use today such as inhalational delivery through smoking.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $30.8M
- Funding stage: IPO
- Last round: Post-IPO Equity (Dec 2025)
- Ticker: nasdaq:LEXX
- Website: lexariabioscience.com
- Phone: 1.250-765.6424
Industries & Categories
Life Science, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/lexaria-bioscience-60231 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.